{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:15:07Z","timestamp":1793128507449,"version":"4.5.0"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s40265-021-01528-8","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T06:02:56Z","timestamp":1620885776000},"page":"985-1002","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":194,"title":["Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis"],"prefix":"10.1007","volume":"81","author":[{"given":"Tamara","family":"P\u00e9rez-Jeldres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Alvarez-Lobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7887-7959","authenticated-orcid":false,"given":"Jes\u00fas","family":"Rivera-Nieves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,13]]},"reference":[{"issue":"9","key":"1528_CR1","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nrd4099","volume":"12","author":"GT Kunkel","year":"2013","unstructured":"Kunkel GT, Maceyka M, Milstien S, Spiegel S. Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013;12(9):688\u2013702.","journal-title":"Nat Rev Drug Discov."},{"issue":"1","key":"1528_CR2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4062\/biomolther.2016.160","volume":"25","author":"SJ Park","year":"2017","unstructured":"Park SJ, Im DS. Sphingosine 1-phosphate receptor modulators and drug discovery. Biomol Ther (Seoul). 2017;25(1):80\u201390.","journal-title":"Biomol Ther (Seoul)."},{"issue":"5","key":"1528_CR3","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.autrev.2017.03.007","volume":"16","author":"L Peyrin-Biroulet","year":"2017","unstructured":"Peyrin-Biroulet L, Christopher R, Behan D, Lassen C. Modulation of sphingosine-1-phosphate in inflammatory bowel disease. Autoimmun Rev. 2017;16(5):495\u2013503.","journal-title":"Autoimmun Rev."},{"issue":"2","key":"1528_CR4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40265-020-01431-8","volume":"81","author":"J Chun","year":"2021","unstructured":"Chun J, Giovannoni G, Hunter SF. Sphingosine 1-phosphate receptor modulator therapy for multiple sclerosis: differential downstream receptor signalling and clinical profile effects. Drugs. 2021;81(2):207\u201331.","journal-title":"Drugs"},{"issue":"11","key":"1528_CR5","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s40265-016-0603-2","volume":"76","author":"HC Tsai","year":"2016","unstructured":"Tsai HC, Han MH. Sphingosine-1-phosphate (S1P) and S1P signaling pathway: therapeutic targets in autoimmunity and inflammation. Drugs. 2016;76(11):1067\u201379.","journal-title":"Drugs"},{"key":"1528_CR6","doi-asserted-by":"crossref","first-page":"104170","DOI":"10.1016\/j.phrs.2019.02.009","volume":"154","author":"B Stepanovska","year":"2020","unstructured":"Stepanovska B, Huwiler A. Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases. Pharmacol Res. 2020;154:104170.","journal-title":"Pharmacol Res."},{"issue":"6463","key":"1528_CR7","doi-asserted-by":"crossref","first-page":"eaar5551","DOI":"10.1126\/science.aar5551","volume":"366","author":"A Cartier","year":"2019","unstructured":"Cartier A, Hla T. Sphingosine 1-phosphate: lipid signaling in pathology and therapy. Science. 2019;366(6463):eaar5551.","journal-title":"Science"},{"key":"1528_CR8","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3389\/fphar.2017.00400","volume":"8","author":"D Curr\u00f2","year":"2017","unstructured":"Curr\u00f2 D, Pugliese D, Armuzzi A. Frontiers in drug research and development for inflammatory bowel disease. Front Pharmacol. 2017;8:400.","journal-title":"Front Pharmacol."},{"issue":"4","key":"1528_CR9","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/14712598.2020.1732919","volume":"20","author":"M Argollo","year":"2020","unstructured":"Argollo M, Furfaro F, Gilardi D, et al. Modulation of sphingosine-1-phosphate in ulcerative colitis. Expert Opin Biol Ther. 2020;20(4):413\u201320.","journal-title":"Expert Opin Biol Ther."},{"issue":"10","key":"1528_CR10","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nri2400","volume":"8","author":"J Rivera","year":"2008","unstructured":"Rivera J, Proia RL, Olivera A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol. 2008;8(10):753\u201363.","journal-title":"Nat Rev Immunol."},{"issue":"4","key":"1528_CR11","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1172\/JCI76369","volume":"125","author":"RL Proia","year":"2015","unstructured":"Proia RL, Hla T. Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. J Clin Invest. 2015;125(4):1379\u201387.","journal-title":"J Clin Invest."},{"key":"1528_CR12","first-page":"8606878","volume":"2016","author":"M Aoki","year":"2016","unstructured":"Aoki M, Aoki H, Ramanathan R, Hait NC, Takabe K. Sphingosine-1-phosphate signaling in immune cells and inflammation: roles and therapeutic potential. Mediators Inflamm. 2016;2016:8606878.","journal-title":"Mediators Inflamm."},{"key":"1528_CR13","doi-asserted-by":"crossref","first-page":"6059203","DOI":"10.1155\/2017\/6059203","volume":"2017","author":"C Olesch","year":"2017","unstructured":"Olesch C, Ringel C, Br\u00fcne B, Weigert A. Beyond immune cell migration: the emerging role of the sphingosine-1-phosphate receptor S1PR4 as a modulator of innate immune cell activation. Mediat Inflamm. 2017;2017:6059203.","journal-title":"Mediat Inflamm."},{"issue":"15","key":"1528_CR14","doi-asserted-by":"crossref","first-page":"9660","DOI":"10.1074\/jbc.M114.609685","volume":"290","author":"ES Park","year":"2015","unstructured":"Park ES, Choi S, Shin B, et al. Tumor necrosis factor (TNF) receptor-associated factor (TRAF)-interacting protein (TRIP) negatively regulates the TRAF2 ubiquitin-dependent pathway by suppressing the TRAF2-sphingosine 1-phosphate (S1P) interaction. J Biol Chem. 2015;290(15):9660\u201373.","journal-title":"J Biol Chem."},{"issue":"5","key":"1528_CR15","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/cmi.2014.35","volume":"11","author":"T Wang","year":"2014","unstructured":"Wang T, Wang J. K63-linked polyubiquitination of IRF1: an essential step in the IL-1 signaling cascade. Cell Mol Immunol. 2014;11(5):407\u20139.","journal-title":"Cell Mol Immunol."},{"issue":"3","key":"1528_CR16","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/ni.2810","volume":"15","author":"KB Harikumar","year":"2014","unstructured":"Harikumar KB, Yester JW, Surace MJ, et al. K63-linked polyubiquitination of transcription factor IRF1 is essential for IL-1-induced production of chemokines CXCL10 and CCL5. Nat Immunol. 2014;15(3):231\u20138.","journal-title":"Nat Immunol."},{"issue":"8","key":"1528_CR17","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1194\/jlr.R046300","volume":"55","author":"VA Blaho","year":"2014","unstructured":"Blaho VA, Hla T. An update on the biology of sphingosine 1-phosphate receptors. J Lipid Res. 2014;55(8):1596\u2013608.","journal-title":"J Lipid Res."},{"issue":"5","key":"1528_CR18","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2011.267","volume":"31","author":"S Spiegel","year":"2012","unstructured":"Spiegel S, Milstien S, Grant S. Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene. 2012;31(5):537\u201351.","journal-title":"Oncogene"},{"issue":"5945","key":"1528_CR19","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1126\/science.1176709","volume":"325","author":"NC Hait","year":"2009","unstructured":"Hait NC, Allegood J, Maceyka M, et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science. 2009;325(5945):1254\u20137.","journal-title":"Science"},{"key":"1528_CR20","first-page":"4806541","volume":"2017","author":"NC Hait","year":"2017","unstructured":"Hait NC, Maiti A. The role of sphingosine-1-phosphate and ceramide-1-phosphate in inflammation and cancer. Mediat Inflamm. 2017;2017:4806541.","journal-title":"Mediat Inflamm."},{"issue":"7301","key":"1528_CR21","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/nature09128","volume":"465","author":"SE Alvarez","year":"2010","unstructured":"Alvarez SE, Harikumar KB, Hait NC, et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature. 2010;465(7301):1084\u20138.","journal-title":"Nature"},{"issue":"4","key":"1528_CR22","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.molmed.2017.02.002","volume":"23","author":"OH Nielsen","year":"2017","unstructured":"Nielsen OH, Li Y, Johansson-Lindbom B, Coskun M. Sphingosine-1-phosphate signaling in inflammatory bowel disease. Trends Mol Med. 2017;23(4):362\u201374.","journal-title":"Trends Mol Med."},{"key":"1528_CR23","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fphar.2019.00212","volume":"10","author":"T P\u00e9rez-Jeldres","year":"2019","unstructured":"P\u00e9rez-Jeldres T, Tyler CJ, Boyer JD, et al. Targeting cytokine signaling and lymphocyte traffic via small molecules in inflammatory bowel disease: JAK inhibitors and S1PR agonists. Front Pharmacol. 2019;10:212.","journal-title":"Front Pharmacol."},{"issue":"2","key":"1528_CR24","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/ibd\/izz174","volume":"26","author":"T Karuppuchamy","year":"2020","unstructured":"Karuppuchamy T, Tyler CJ, Lundborg LR, et al. Sphingosine-1-phosphate lyase inhibition alters the S1P gradient and ameliorates Crohn\u2019s-like ileitis by suppressing thymocyte maturation. Inflamm Bowel Dis. 2020;26(2):216\u201328.","journal-title":"Inflamm Bowel Dis."},{"issue":"11","key":"1528_CR25","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/ni.1939","volume":"11","author":"G Liu","year":"2010","unstructured":"Liu G, Yang K, Burns S, Shrestha S, Chi H. The S1P(1)-mTOR axis directs the reciprocal differentiation of T(H)1 and T(reg) cells. Nat Immunol. 2010;11(11):1047\u201356.","journal-title":"Nat Immunol."},{"issue":"11","key":"1528_CR26","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/ni.2730","volume":"14","author":"CS Garris","year":"2013","unstructured":"Garris CS, Wu L, Acharya S, et al. Defective sphingosine 1-phosphate receptor 1 (S1P1) phosphorylation exacerbates TH17-mediated autoimmune neuroinflammation. Nat Immunol. 2013;14(11):1166\u201372.","journal-title":"Nat Immunol."},{"issue":"7","key":"1528_CR27","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/ni1083","volume":"5","author":"G Cinamon","year":"2004","unstructured":"Cinamon G, Matloubian M, Lesneski MJ, et al. Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone. Nat Immunol. 2004;5(7):713\u201320.","journal-title":"Nat Immunol."},{"issue":"1","key":"1528_CR28","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/mi.2016.35","volume":"10","author":"T Karuppuchamy","year":"2017","unstructured":"Karuppuchamy T, Behrens EH, Gonz\u00e1lez-Cabrera P, et al. Sphingosine-1-phosphate receptor-1 (S1P1) is expressed by lymphocytes, dendritic cells, and endothelium and modulated during inflammatory bowel disease. Mucosal Immunol. 2017;10(1):162\u201371.","journal-title":"Mucosal Immunol."},{"key":"1528_CR29","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fphar.2016.00167","volume":"7","author":"KV Blankenbach","year":"2016","unstructured":"Blankenbach KV, Schwalm S, Pfeilschifter J, Heringdorf DMZ. Sphingosine-1-phosphate receptor-2 antagonists: therapeutic potential and potential risks. Front Pharmacol. 2016;7:167.","journal-title":"Front Pharmacol."},{"issue":"7","key":"1528_CR30","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/ni.2047","volume":"12","author":"JA Green","year":"2011","unstructured":"Green JA, Suzuki K, Cho B, et al. The sphingosine 1-phosphate receptor S1P2 maintains the homeostasis of germinal center B cells and promotes niche confinement. Nat Immunol. 2011;12(7):672\u201380.","journal-title":"Nat Immunol."},{"issue":"7530","key":"1528_CR31","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nature13765","volume":"516","author":"JR Muppidi","year":"2014","unstructured":"Muppidi JR, Schmitz R, Green JA, et al. Loss of signalling via G\u03b113 in germinal centre B-cell-derived lymphoma. Nature. 2014;516(7530):254\u20138.","journal-title":"Nature"},{"issue":"12","key":"1528_CR32","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1096\/fj.05-3730fje","volume":"19","author":"W Wang","year":"2005","unstructured":"Wang W, Graeler MH, Goetzl EJ. Type 4 sphingosine 1-phosphate G protein-coupled receptor (S1P4) transduces S1P effects on T cell proliferation and cytokine secretion without signaling migration. FASEB J. 2005;19(12):1731\u20133.","journal-title":"FASEB J."},{"issue":"11","key":"1528_CR33","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1084\/jem.20090525","volume":"206","author":"CN Jenne","year":"2009","unstructured":"Jenne CN, Enders A, Rivera R, et al. T-bet-dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow. J Exp Med. 2009;206(11):2469\u201381.","journal-title":"J Exp Med."},{"key":"1528_CR34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/1742-2094-9-133","volume":"9","author":"R van Doorn","year":"2012","unstructured":"van Doorn R, Lopes Pinheiro MA, Kooij G, et al. Sphingosine 1-phosphate receptor 5 mediates the immune quiescence of the human brain endothelial barrier. J Neuroinflamm. 2012;9:133.","journal-title":"J Neuroinflamm."},{"key":"1528_CR35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12974-016-0494-x","volume":"13","author":"C O'Sullivan","year":"2016","unstructured":"O\u2019Sullivan C, Schubart A, Mir AK, Dev KK. The dual S1PR1\/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures. J Neuroinflamm. 2016;13:31.","journal-title":"J Neuroinflamm."},{"key":"1528_CR36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/bs.apcsb.2019.11.003","volume":"120","author":"OA Sukocheva","year":"2020","unstructured":"Sukocheva OA, Lukina E, McGowan E, Bishayee A. Sphingolipids as mediators of inflammation and novel therapeutic target in inflammatory bowel disease. Adv Protein Chem Struct Biol. 2020;120:123\u201358.","journal-title":"Adv Protein Chem Struct Biol."},{"issue":"1","key":"1528_CR37","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/bph.13641","volume":"174","author":"K Sugahara","year":"2017","unstructured":"Sugahara K, Maeda Y, Shimano K, et al. Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk. Br J Pharmacol. 2017;174(1):15\u201327.","journal-title":"Br J Pharmacol."},{"issue":"6","key":"1528_CR38","doi-asserted-by":"crossref","first-page":"e00370","DOI":"10.1002\/prp2.370","volume":"5","author":"L Piali","year":"2017","unstructured":"Piali L, Birker-Robaczewska M, Lescop C, et al. Cenerimod, a novel selective S1P1 receptor modulator with unique signaling properties. Pharmacol Res Perspect. 2017;5(6):e00370.","journal-title":"Pharmacol Res Perspect."},{"issue":"8","key":"1528_CR39","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/17425255.2016.1196188","volume":"12","author":"PE Juif","year":"2016","unstructured":"Juif PE, Kraehenbuehl S, Dingemanse J. Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators. Expert Opin Drug Metab Toxicol. 2016;12(8):879\u201395.","journal-title":"Expert Opin Drug Metab Toxicol."},{"issue":"11","key":"1528_CR40","first-page":"1183","volume":"10","author":"L Japtok","year":"2009","unstructured":"Japtok L, Kleuser B. The role of sphingosine-1-phosphate receptor modulators in the prevention of transplant rejection and autoimmune diseases. Curr Opin Investig Drugs. 2009;10(11):1183\u201394.","journal-title":"Curr Opin Investig Drugs."},{"issue":"12","key":"1528_CR41","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1111\/j.1600-6143.2006.01552.x","volume":"6","author":"M Salvadori","year":"2006","unstructured":"Salvadori M, Budde K, Charpentier B, et al. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am J Transplant. 2006;6(12):2912\u201321.","journal-title":"Am J Transplant."},{"issue":"6","key":"1528_CR42","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","volume":"13","author":"PA Calabresi","year":"2014","unstructured":"Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(6):545\u201356.","journal-title":"Lancet Neurol."},{"key":"1528_CR43","first-page":"CD009371","volume":"4","author":"L La Mantia","year":"2016","unstructured":"La Mantia L, Tramacere I, Firwana B, Pacchetti I, Palumbo R, Filippini G. Fingolimod for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev. 2016;4:CD009371.","journal-title":"Cochrane Database Syst Rev."},{"issue":"2","key":"1528_CR44","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/annrheumdis-2017-211555","volume":"77","author":"KF Baker","year":"2018","unstructured":"Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn\u2019s disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175\u201387.","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"1528_CR45","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.msard.2013.11.006","volume":"3","author":"BO Khatri","year":"2014","unstructured":"Khatri BO, Pelletier J, Kappos L, et al. Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon \u03b2-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS). Mult Scler Relat Disord. 2014;3(3):355\u201363.","journal-title":"Mult Scler Relat Disord."},{"issue":"1","key":"1528_CR46","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.mayocp.2018.09.013","volume":"94","author":"GP Ramos","year":"2019","unstructured":"Ramos GP, Papadakis KA. Mechanisms of disease: inflammatory bowel diseases. Mayo Clin Proc. 2019;94(1):155\u201365.","journal-title":"Mayo Clin Proc."},{"key":"1528_CR47","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1146\/annurev-immunol-042617-053055","volume":"36","author":"HH Uhlig","year":"2018","unstructured":"Uhlig HH, Powrie F. Translating immunology into therapeutic concepts for inflammatory bowel disease. Annu Rev Immunol. 2018;36:755\u201381.","journal-title":"Annu Rev Immunol."},{"issue":"3","key":"1528_CR48","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/00054725-200405000-00002","volume":"10","author":"T Mizushima","year":"2004","unstructured":"Mizushima T, Ito T, Kishi D, et al. Therapeutic effects of a new lymphocyte homing reagent FTY720 in interleukin-10 gene-deficient mice with colitis. Inflamm Bowel Dis. 2004;10(3):182\u201392.","journal-title":"Inflamm Bowel Dis."},{"key":"1528_CR49","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pharmthera.2017.11.001","volume":"185","author":"A Huwiler","year":"2018","unstructured":"Huwiler A, Zangemeister-Wittke U. The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives. Pharmacol Ther. 2018;185:34\u201349.","journal-title":"Pharmacol Ther."},{"issue":"4","key":"1528_CR50","first-page":"699","volume":"16","author":"Y Deguchi","year":"2006","unstructured":"Deguchi Y, Andoh A, Yagi Y, et al. The S1P receptor modulator FTY720 prevents the development of experimental colitis in mice. Oncol Rep. 2006;16(4):699\u2013703.","journal-title":"Oncol Rep."},{"issue":"4","key":"1528_CR51","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.4049\/jimmunol.178.4.2458","volume":"178","author":"C Daniel","year":"2007","unstructured":"Daniel C, Sartory N, Zahn N, Geisslinger G, Radeke HH, Stein JM. FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells. J Immunol. 2007;178(4):2458\u201368.","journal-title":"J Immunol."},{"issue":"8","key":"1528_CR52","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1007\/s10620-011-1628-8","volume":"56","author":"ZA Radi","year":"2011","unstructured":"Radi ZA, Heuvelman DM, Masferrer JL, Benson EL. Pharmacologic evaluation of sulfasalazine, FTY720, and anti-IL-12\/23p40 in a TNBS-induced Crohn\u2019s disease model. Dig Dis Sci. 2011;56(8):2283\u201391.","journal-title":"Dig Dis Sci."},{"issue":"3","key":"1528_CR53","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1194\/jlr.M034108","volume":"54","author":"DC Montrose","year":"2013","unstructured":"Montrose DC, Scherl EJ, Bosworth BP, et al. S1P1 localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity. J Lipid Res. 2013;54(3):843\u201351.","journal-title":"J Lipid Res."},{"key":"1528_CR54","doi-asserted-by":"crossref","first-page":"109","DOI":"10.12703\/P6-109","volume":"6","author":"PJ Gonzalez-Cabrera","year":"2014","unstructured":"Gonzalez-Cabrera PJ, Brown S, Studer SM, Rosen H. S1P signaling: new therapies and opportunities. F1000Prime Rep. 2014;6:109.","journal-title":"F1000Prime Rep."},{"issue":"4","key":"1528_CR55","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000509393","volume":"5","author":"H Radeke","year":"2020","unstructured":"Radeke H, Stein J, Van Assche G, Rogler G, Lakatos P, Muellershausen F, Moulin P, Jarvis P, Colin L, Gergely P, Kruis W. A multicentre, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of the s1p receptor agonist KRP203 in patients with moderately active refractory ulcerative colitis. Inflamm Intest Dis. 2020;5(4):180\u201390.","journal-title":"Inflamm Intest Dis."},{"issue":"12","key":"1528_CR56","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/ibd.20520","volume":"14","author":"JD Lewis","year":"2008","unstructured":"Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14(12):1660\u20136.","journal-title":"Inflamm Bowel Dis."},{"issue":"5375","key":"1528_CR57","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/bmj.1.5375.89","volume":"1","author":"JH Baron","year":"1964","unstructured":"Baron JH, Connell AM, Lennard-Jones JE. variation between observers in describing mucosal appearances in proctocolitis. Br Med J. 1964;1(5375):89\u201392.","journal-title":"Br Med J."},{"issue":"8","key":"1528_CR58","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40265-020-01319-7","volume":"80","author":"YN Lamb","year":"2020","unstructured":"Lamb YN. Ozanimod: first approval. Drugs. 2020;80(8):841\u20138.","journal-title":"Drugs"},{"issue":"12","key":"1528_CR59","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1093\/ibd\/izy189","volume":"24","author":"A Hemperly","year":"2018","unstructured":"Hemperly A, Sandborn WJ, Vande CN. Clinical pharmacology in adult and pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2018;24(12):2527\u201342.","journal-title":"Inflamm Bowel Dis."},{"issue":"11","key":"1528_CR60","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/bph.13476","volume":"173","author":"FL Scott","year":"2016","unstructured":"Scott FL, Clemons B, Brooks J, et al. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity. Br J Pharmacol. 2016;173(11):1778\u201392.","journal-title":"Br J Pharmacol."},{"issue":"4","key":"1528_CR61","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S1474-4422(19)30391-6","volume":"19","author":"T Derfuss","year":"2020","unstructured":"Derfuss T, Mehling M, Papadopoulou A, Bar-Or A, Cohen JA, Kappos L. Advances in oral immunomodulating therapies in relapsing multiple sclerosis. Lancet Neurol. 2020;19(4):336\u201347.","journal-title":"Lancet Neurol."},{"issue":"18","key":"1528_CR62","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","volume":"374","author":"WJ Sandborn","year":"2016","unstructured":"Sandborn WJ, Feagan BG, Wolf DC, et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med. 2016;374(18):1754\u201362.","journal-title":"N Engl J Med."},{"key":"1528_CR63","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Feagan BG, Hanauer S, et al. Long-term efficacy and safety of ozanimod in moderate-to-severe ulcerative colitis: results from the open-label extension of the randomized, phase 2 touchstone study [published online ahead of print, 2021 Jan 13]. J Crohns Colitis. 2021;jjab012.","DOI":"10.1093\/ecco-jcc\/jjab012"},{"key":"1528_CR64","unstructured":"Sandborn, WJ, D\u2019Haens G, Wolf D, Hanauer S, Jovanovic I, Ghosh S, et al. \u201cLB5\u2014(Late-Breaking Abstract) Ozanimod for Moderate-to-Severe Ulcerative Colitis: Efficacy, Safety, and Histology Results from the Induction and Maintenance Periods of the Phase 3 True North Study,\u201d ACG 2020. https:\/\/www.eventscribe.com\/2020\/ACG\/fsPopup.asp?efp=RElCSUFHUk02NDI2&PresentationID=783287&rnd=0.4752997&mode=presinfo. Accessed 24 Dec 2020."},{"issue":"9","key":"1528_CR65","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S2468-1253(20)30188-6","volume":"5","author":"BG Feagan","year":"2020","unstructured":"Feagan BG, Sandborn WJ, Danese S, et al. Ozanimod induction therapy for patients with moderate to severe Crohn\u2019s disease: a single-arm, phase 2, prospective observer-blinded endpoint study. Lancet Gastroenterol Hepatol. 2020;5(9):819\u201328.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"5","key":"1528_CR66","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1053\/j.gastro.2013.08.010","volume":"145","author":"M Ferrante","year":"2013","unstructured":"Ferrante M, Colombel JF, Sandborn WJ, et al. Validation of endoscopic activity scores in patients with Crohn\u2019s disease based on a post hoc analysis of data from SONIC. Gastroenterology. 2013;145(5):978-986.e5.","journal-title":"Gastroenterology"},{"issue":"3","key":"1528_CR67","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","volume":"70","author":"WR Best","year":"1976","unstructured":"Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn\u2019s disease activity index. National Cooperative Crohn\u2019s Disease Study. Gastroenterology. 1976;70(3):439\u201344.","journal-title":"Gastroenterology"},{"issue":"1","key":"1528_CR68","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/apt.13001","volume":"41","author":"R Khanna","year":"2015","unstructured":"Khanna R, Zou G, D\u2019Haens G, et al. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn\u2019s disease activity. Aliment Pharmacol Ther. 2015;41(1):77\u201386.","journal-title":"Aliment Pharmacol Ther."},{"issue":"3","key":"1528_CR69","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/gut.47.3.404","volume":"47","author":"K Geboes","year":"2000","unstructured":"Geboes K, Riddell R, Ost A, Jensfelt B, Persson T, L\u00f6fberg R. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000;47(3):404\u20139.","journal-title":"Gut"},{"issue":"11","key":"1528_CR70","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1136\/gutjnl-2018-317547","volume":"68","author":"RK Pai","year":"2019","unstructured":"Pai RK, Khanna R, D\u2019Haens GR, et al. Definitions of response and remission for the Robarts Histopathology Index. Gut. 2019;68(11):2101\u20132.","journal-title":"Gut"},{"issue":"3","key":"1528_CR71","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1124\/jpet.118.254268","volume":"369","author":"H Al-Shamma","year":"2019","unstructured":"Al-Shamma H, Lehmann-Bruinsma K, Carroll C, et al. The selective sphingosine 1-phosphate receptor modulator etrasimod regulates lymphocyte trafficking and alleviates experimental colitis. J Pharmacol Exp Ther. 2019;369(3):311\u20137.","journal-title":"J Pharmacol Exp Ther."},{"issue":"3","key":"1528_CR72","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Peyrin-Biroulet L, Zhang J, et al. Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis. Gastroenterology. 2020;158(3):550\u201361.","journal-title":"Gastroenterology"},{"key":"1528_CR73","unstructured":"Kashou AH, Goyal A, Nguyen T, Chhabra L. Atrioventricular block. In: StatPearls. Treasure Island: StatPearls Publishing; 2021."},{"key":"1528_CR74","doi-asserted-by":"crossref","first-page":"5821589","DOI":"10.1155\/2019\/5821589","volume":"2019","author":"K Sugahara","year":"2019","unstructured":"Sugahara K, Maeda Y, Shimano K, et al. Amiselimod (MT-1303), a novel sphingosine 1-phosphate receptor-1 modulator, potently inhibits the progression of lupus nephritis in two murine SLE models. J Immunol Res. 2019;2019:5821589.","journal-title":"J Immunol Res."},{"issue":"12","key":"1528_CR75","doi-asserted-by":"crossref","first-page":"e0226154","DOI":"10.1371\/journal.pone.0226154","volume":"14","author":"K Shimano","year":"2019","unstructured":"Shimano K, Maeda Y, Kataoka H, et al. Amiselimod (MT-1303), a novel sphingosine 1-phosphate receptor-1 functional antagonist, inhibits progress of chronic colitis induced by transfer of CD4+CD45RBhigh T cells. PLoS ONE. 2019;14(12):e0226154.","journal-title":"PLoS ONE"},{"issue":"12","key":"1528_CR76","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1177\/1352458517728343","volume":"24","author":"L Kappos","year":"2018","unstructured":"Kappos L, Arnold DL, Bar-Or A, et al. Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis. Mult Scler. 2018;24(12):1605\u201316.","journal-title":"Mult Scler."},{"key":"1528_CR77","unstructured":"A clinical study to investigate the effects of MT-1303 on patients with moderate to severe Chronic Plaque Psoriasis focusing on how safe, tolerable and effective in treating the above condition MT-1303 is. https:\/\/www.cochranelibrary.com\/es\/central\/doi\/10.1002\/central\/CN-01799880\/full. Accessed 12 Apr 2021."},{"key":"1528_CR78","doi-asserted-by":"publisher","first-page":"S-217","DOI":"10.1016\/S0016-5085(19)37337-8","volume":"156","author":"G D\u2019Haens","year":"2019","unstructured":"D\u2019Haens G, Danese S, Hibi T, Watanabe M, Davies M. 1005\u2013a controlled trial of amiselimod, a selective S1P receptor modulator in Crohn\u2019s disease. Gastroenterology. 2019;156:S-217. https:\/\/doi.org\/10.1016\/S0016-5085(19)37337-8.","journal-title":"Gastroenterology"},{"key":"1528_CR79","unstructured":"Bausch Health picks up IBD drug amiselimod rejected by Biogen. https:\/\/www.thepharmaletter.com\/article\/bausch-health-picks-up-ibd-drug-amiselimod-rejected-by-biogen. Accessed 7 Feb 2021."},{"key":"1528_CR80","doi-asserted-by":"crossref","unstructured":"D\u2019Haens, G. R. A. M., Slatkin, N, Israel, R, Heimanson Z. P097(Abstract).Favorable safety profile for amiselimod, a selective s1p receptor modulator, in Crohn\u2019s Disease. Gastroenterology. 2020;150(3S):S2.","DOI":"10.1053\/j.gastro.2019.11.044"},{"key":"1528_CR81","unstructured":"MT. Pharma. \u201c6 State of New Product development\u201d. https:\/\/www.mt-pharma.co.jp\/e\/develop\/assets\/pdf\/e_pipeline2012.pdf. Accessed 7 Feb 2021."},{"key":"1528_CR82","doi-asserted-by":"publisher","unstructured":"Stephen H, O\u2019Reilly T, Lester R, Slatkin N, Lee J, Franklin H, Bulawski A, Israel R. Safety of amiselimod in healthy subjects: results from a phase 1 randomized, double-blind, placebo-controlled study. Inflamm Bowel Dis (Abstract). 2021;27(Supplement_1):S1. https:\/\/doi.org\/10.1093\/ibd\/izaa347.001","DOI":"10.1093\/ibd\/izaa347.001"},{"key":"1528_CR83","doi-asserted-by":"crossref","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","volume":"2","author":"JE Greb","year":"2016","unstructured":"Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:16082.","journal-title":"Nat Rev Dis Primers."},{"issue":"19","key":"1528_CR84","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1016\/j.bmcl.2018.07.044","volume":"28","author":"M Bell","year":"2018","unstructured":"Bell M, Foley D, Naylor C, et al. Discovery of super soft-drug modulators of sphingosine-1-phosphate receptor 1. Bioorg Med Chem Lett. 2018;28(19):3255\u20139.","journal-title":"Bioorg Med Chem Lett."},{"issue":"9959","key":"1528_CR85","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0140-6736(14)60803-5","volume":"384","author":"A Vaclavkova","year":"2014","unstructured":"Vaclavkova A, Chimenti S, Arenberger P, et al. Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2014;384(9959):2036\u201345.","journal-title":"Lancet"},{"issue":"20","key":"1528_CR86","doi-asserted-by":"crossref","first-page":"7488","DOI":"10.3390\/ijms21207488","volume":"21","author":"M Tokuyama","year":"2020","unstructured":"Tokuyama M, Mabuchi T. New treatment addressing the pathogenesis of psoriasis. Int J Mol Sci. 2020;21(20):7488.","journal-title":"Int J Mol Sci."},{"issue":"9959","key":"1528_CR87","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/S0140-6736(14)61039-4","volume":"384","author":"C Ryan","year":"2014","unstructured":"Ryan C, Menter A. Ponesimod\u2014a future oral therapy for psoriasis? Lancet. 2014;384(9959):2006\u20138.","journal-title":"Lancet"},{"issue":"3","key":"1528_CR88","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/jcph.820","volume":"57","author":"PE Juif","year":"2017","unstructured":"Juif PE, Hoch M, Vaclavkova A, Krause A, Bush J, Dingemanse J. Mitigation of initial cardiodynamic effects of the S1P1 receptor modulator ponesimod using a novel up-titration regimen. J Clin Pharmacol. 2017;57(3):401\u201310.","journal-title":"J Clin Pharmacol."},{"issue":"2","key":"1528_CR89","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.apsb.2019.11.006","volume":"10","author":"J Jin","year":"2020","unstructured":"Jin J, Xue N, Liu Y, et al. A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models. Acta Pharm Sin B. 2020;10(2):276\u201388.","journal-title":"Acta Pharm Sin B."},{"issue":"1","key":"1528_CR90","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.det.2018.07.003","volume":"37","author":"A Kusari","year":"2019","unstructured":"Kusari A, Han AM, Schairer D, Eichenfield LF. Atopic dermatitis: new developments. Dermatol Clin. 2019;37(1):11\u201320.","journal-title":"Dermatol Clin."},{"issue":"10055","key":"1528_CR91","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023\u201338.","journal-title":"Lancet"},{"key":"1528_CR92","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.clim.2016.11.008","volume":"175","author":"Y Mao-Draayer","year":"2017","unstructured":"Mao-Draayer Y, Sarazin J, Fox D, Schiopu E. The sphingosine-1-phosphate receptor: a novel therapeutic target for multiple sclerosis and other autoimmune diseases. Clin Immunol. 2017;175:10\u20135.","journal-title":"Clin Immunol."},{"issue":"11","key":"1528_CR93","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1194\/jlr.M800143-JLR200","volume":"49","author":"C Zhao","year":"2008","unstructured":"Zhao C, Fernandes MJ, Turgeon M, et al. Specific and overlapping sphingosine-1-phosphate receptor functions in human synoviocytes: impact of TNF-alpha. J Lipid Res. 2008;49(11):2323\u201337.","journal-title":"J Lipid Res."},{"issue":"2","key":"1528_CR94","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.clim.2010.03.428","volume":"136","author":"S Tsunemi","year":"2010","unstructured":"Tsunemi S, Iwasaki T, Kitano S, Imado T, Miyazawa K, Sano H. Effects of the novel immunosuppressant FTY720 in a murine rheumatoid arthritis model. Clin Immunol. 2010;136(2):197\u2013204.","journal-title":"Clin Immunol."},{"issue":"12","key":"1528_CR95","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1021\/ml500389m","volume":"5","author":"DJ Buzard","year":"2014","unstructured":"Buzard DJ, Kim SH, Lopez L, et al. Discovery of APD334: design of a clinical stage functional antagonist of the sphingosine-1-phosphate-1 receptor. ACS Med Chem Lett. 2014;5(12):1313\u20137.","journal-title":"ACS Med Chem Lett."},{"key":"1528_CR96","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3389\/fphar.2019.01085","volume":"10","author":"J Jin","year":"2019","unstructured":"Jin J, Ji M, Fu R, et al. Sphingosine-1-phosphate receptor subtype 1 (S1P1) modulator IMMH001 regulates adjuvant- and collagen-induced arthritis. Front Pharmacol. 2019;10:1085.","journal-title":"Front Pharmacol."},{"key":"1528_CR97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.11.001","volume":"96","author":"A Fava","year":"2019","unstructured":"Fava A, Petri M. Systemic lupus erythematosus: diagnosis and clinical management. J Autoimmun. 2019;96:1\u201313.","journal-title":"J Autoimmun."},{"issue":"4","key":"1528_CR98","doi-asserted-by":"crossref","first-page":"e0193236","DOI":"10.1371\/journal.pone.0193236","volume":"13","author":"KR Taylor Meadows","year":"2018","unstructured":"Taylor Meadows KR, Steinberg MW, Clemons B, et al. Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus. PLoS ONE. 2018;13(4):e0193236.","journal-title":"PLoS ONE"},{"issue":"1","key":"1528_CR99","first-page":"81","volume":"93","author":"AJ Little","year":"2020","unstructured":"Little AJ, Vesely MD. Cutaneous lupus erythematosus: current and future pathogenesis-directed therapies. Yale J Biol Med. 2020;93(1):81\u201395.","journal-title":"Yale J Biol Med."},{"key":"1528_CR100","unstructured":"Gerossier E, Nayar S, Smith C, Froidevaux S, Barone F, Martinic M. Cenerimod, a potent and selective sphingosine-1-phosphate receptor 1 modulator, controls systemic autoimmunity and organ pathology in mouse models of systemic lupus erythematosus and Sj\u00f6gren\u2019s syndrome [abstract]. Arthritis Rheumatol. 2019;71(suppl 10). https:\/\/acrabstracts.org\/abstract\/cenerimod-a-potent-and-selective-sphingosine-1-phosphate-receptor-1-modulator-controls-systemic-autoimmunity-and-organ-pathology-in-mouse-models-of-systemic-lupus-erythematosus-and-sjogrens\/. Accessed 25 Sept 2020."},{"issue":"1","key":"1528_CR101","doi-asserted-by":"crossref","first-page":"e000354","DOI":"10.1136\/lupus-2019-000354","volume":"6","author":"V Hermann","year":"2019","unstructured":"Hermann V, Batalov A, Smakotina S, Juif PE, Cornelisse P. First use of cenerimod, a selective S1P1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study. Lupus Sci Med. 2019;6(1):e000354.","journal-title":"Lupus Sci Med."},{"issue":"2","key":"1528_CR102","doi-asserted-by":"crossref","first-page":"e001261","DOI":"10.1136\/rmdopen-2020-001261","volume":"6","author":"DS Strasser","year":"2020","unstructured":"Strasser DS, Froidevaux S, Sippel V, et al. Preclinical to clinical translation of cenerimod, a novel S1P1 receptor modulator, in systemic lupus erythematosus. RMD Open. 2020;6(2):e001261.","journal-title":"RMD Open"},{"issue":"14","key":"1528_CR103","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1177\/0961203320966385","volume":"29","author":"Y Tanaka","year":"2020","unstructured":"Tanaka Y, Kondo K, Ichibori A, et al. Amiselimod, a sphingosine 1-phosphate receptor-1 modulator, for systemic lupus erythematosus: a multicenter, open-label exploratory study. Lupus. 2020;29(14):1902\u201313.","journal-title":"Lupus"},{"issue":"2","key":"1528_CR104","first-page":"288","volume":"29","author":"DD Gladman","year":"2002","unstructured":"Gladman DD, Iba\u00f1ez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288\u201391.","journal-title":"J Rheumatol."},{"issue":"1\u20132","key":"1528_CR105","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jneuroim.2012.03.007","volume":"246","author":"JB Moberly","year":"2012","unstructured":"Moberly JB, Ford DM, Zahir H, et al. Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: results from a 12-week, open-label pilot study in multiple sclerosis patients. J Neuroimmunol. 2012;246(1\u20132):100\u20137.","journal-title":"J Neuroimmunol."},{"issue":"3","key":"1528_CR106","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/cpdd.98","volume":"3","author":"J Xu","year":"2014","unstructured":"Xu J, Gray F, Henderson A, et al. Safety, pharmacokinetics, pharmacodynamics, and bioavailability of GSK2018682, a sphingosine-1-phosphate receptor modulator, in healthy volunteers. Clin Pharmacol Drug Dev. 2014;3(3):170\u20138.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"1","key":"1528_CR107","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jamaneurol.2014.3065","volume":"72","author":"AM Arvin","year":"2015","unstructured":"Arvin AM, Wolinsky JS, Kappos L, et al. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol. 2015;72(1):31\u20139.","journal-title":"JAMA Neurol."},{"key":"1528_CR108","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.clinimag.2018.11.005","volume":"54","author":"I Chong","year":"2019","unstructured":"Chong I, Wang KY, Lincoln CM. Cryptococcal meningitis in a multiple sclerosis patient treated with fingolimod: a case report and review of imaging findings. Clin Imaging. 2019;54:53\u20136.","journal-title":"Clin Imaging."},{"issue":"23","key":"1528_CR109","doi-asserted-by":"crossref","first-page":"6377","DOI":"10.1016\/j.bmcl.2013.09.058","volume":"23","author":"M Urbano","year":"2013","unstructured":"Urbano M, Guerrero M, Rosen H, Roberts E. Modulators of the sphingosine 1-phosphate receptor 1. Bioorg Med Chem Lett. 2013;23(23):6377\u201389.","journal-title":"Bioorg Med Chem Lett."},{"issue":"13","key":"1528_CR110","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.3390\/ijms20133232","volume":"20","author":"PE Juif","year":"2019","unstructured":"Juif PE, Ufer M, Dingemanse J. Cardiodynamic interactions between two S1P1 receptor modulators in an experimental clinical setting: different pharmacokinetic properties as an opportunity to mitigate first-dose heart rate effects. Int J Mol Sci. 2019;20(13):3232.","journal-title":"Int J Mol Sci."},{"issue":"9","key":"1528_CR111","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s40265-019-01140-x","volume":"79","author":"ZT Al-Salama","year":"2019","unstructured":"Al-Salama ZT. Siponimod: first global approval. Drugs. 2019;79(9):1009\u201315.","journal-title":"Drugs"},{"key":"1528_CR112","unstructured":"Novartis Pharmaceuticals Corporation. MAYZENT\u00ae (siponimod): US prescribing information 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/209884s000lbl.pdf. Accessed 7 Feb 2021."},{"key":"1528_CR113","doi-asserted-by":"crossref","first-page":"175628641987832","DOI":"10.1177\/1756286419878324","volume":"12","author":"JA Cohen","year":"2019","unstructured":"Cohen JA, Tenenbaum N, Bhatt A, Zhang Y, Kappos L. Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results. Ther Adv Neurol Disord. 2019;12:1756286419878324.","journal-title":"Ther Adv Neurol Disord."},{"key":"1528_CR114","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.msard.2018.04.018","volume":"23","author":"MD Benedetti","year":"2018","unstructured":"Benedetti MD, Marangi A, Bozzetti S, et al. HPV-related papillary squamous cell carcinoma of the tonsil during treatment with fingolimod. Mult Scler Relat Disord. 2018;23:24\u20136.","journal-title":"Mult Scler Relat Disord."},{"key":"1528_CR115","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jss.2018.05.085","volume":"231","author":"K Yuza","year":"2018","unstructured":"Yuza K, Nagahashi M, Shimada Y, et al. Upregulation of phosphorylated sphingosine kinase 1 expression in colitis-associated cancer. J Surg Res. 2018;231:323\u201330.","journal-title":"J Surg Res."},{"key":"1528_CR116","doi-asserted-by":"publisher","DOI":"10.1002\/bab.1922","author":"SG Khoei","year":"2020","unstructured":"Khoei SG, Sadeghi H, Samadi P, Najafi R, Saidijam M. Relationship between Sphk1\/S1P and microRNAs in human cancers. Biotechnol Appl Biochem. 2020. https:\/\/doi.org\/10.1002\/bab.1922.","journal-title":"Biotechnol Appl Biochem."},{"key":"1528_CR117","doi-asserted-by":"crossref","first-page":"107464","DOI":"10.1016\/j.pharmthera.2019.107464","volume":"207","author":"OA Sukocheva","year":"2020","unstructured":"Sukocheva OA, Furuya H, Ng ML, et al. Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: A novel therapeutic target. Pharmacol Ther. 2020;207:107464.","journal-title":"Pharmacol Ther."},{"issue":"5","key":"1528_CR118","first-page":"2450","volume":"41","author":"M Cao","year":"2018","unstructured":"Cao M, Ji C, Zhou Y, et al. Sphingosine kinase inhibitors: a patent review. Int J Mol Med. 2018;41(5):2450\u201360.","journal-title":"Int J Mol Med."},{"key":"1528_CR119","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.prostaglandins.2017.03.006","volume":"130","author":"MJ Pulkoski-Gross","year":"2017","unstructured":"Pulkoski-Gross MJ, Uys JD, Orr-Gandy KA, et al. Novel sphingosine kinase-1 inhibitor, LCL351, reduces immune responses in murine DSS-induced colitis. Prostaglandins Other Lipid Mediat. 2017;130:47\u201356.","journal-title":"Prostaglandins Other Lipid Mediat."},{"issue":"2","key":"1528_CR120","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jaci.2012.07.014","volume":"131","author":"MM Price","year":"2013","unstructured":"Price MM, Oskeritzian CA, Falanga YT, et al. A specific sphingosine kinase 1 inhibitor attenuates airway hyperresponsiveness and inflammation in a mast cell-dependent murine model of allergic asthma. J Allergy Clin Immunol. 2013;131(2):501-11.e1.","journal-title":"J Allergy Clin Immunol."},{"issue":"6","key":"1528_CR121","doi-asserted-by":"crossref","first-page":"594","DOI":"10.2340\/00015555-3160","volume":"99","author":"SH Shin","year":"2019","unstructured":"Shin SH, Cho KA, Hahn S, et al. Inhibiting sphingosine kinase 2 derived-sphingosine-1-phosphate ameliorates psoriasis-like skin disease via blocking Th17 differentiation of na\u00efve CD4 T lymphocytes in mice. Acta Derm Venereol. 2019;99(6):594\u2013601.","journal-title":"Acta Derm Venereol."},{"issue":"8","key":"1528_CR122","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1096\/fj.201600394R","volume":"30","author":"WC Huang","year":"2016","unstructured":"Huang WC, Liang J, Nagahashi M, et al. Sphingosine-1-phosphate phosphatase 2 promotes disruption of mucosal integrity, and contributes to ulcerative colitis in mice and humans. FASEB J. 2016;30(8):2945\u201358.","journal-title":"FASEB J."},{"key":"1528_CR123","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14092","author":"K Shirakabe","year":"2018","unstructured":"Shirakabe K, Higashiyama M, Furuhashi H, et al. Amelioration of colitis through blocking lymphocytes entry to Peyer\u2019s patches by sphingosine-1-phosphate lyase inhibitor. J Gastroenterol Hepatol. 2018. https:\/\/doi.org\/10.1111\/jgh.14092.","journal-title":"J Gastroenterol Hepatol."},{"issue":"12","key":"1528_CR124","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1172\/JCI74188","volume":"124","author":"E Degagn\u00e9","year":"2014","unstructured":"Degagn\u00e9 E, Pandurangan A, Bandhuvula P, et al. Sphingosine-1-phosphate lyase downregulation promotes colon carcinogenesis through STAT3-activated microRNAs. J Clin Invest. 2014;124(12):5368\u201384.","journal-title":"J Clin Invest."},{"key":"1528_CR125","unstructured":"Fleischmann RM, Poiley JE, Stoilov R, et al. The oral S1P lyase inhibitor LX3305 (LX2931) demonstrates favorable safety and potential clinical benefit at 12-weeks in a phase 2 proof-of-concept trial in patients with active rheumatoid arthritis on stable methotrexate. Presentation Number: 2593. 2011. https:\/\/acr.confex.com\/acr\/2011\/webprogram\/Paper19634.html. Accessed 25 Sept 2020"},{"issue":"12","key":"1528_CR126","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1096\/fj.15-274936","volume":"29","author":"MS Donoviel","year":"2015","unstructured":"Donoviel MS, Hait NC, Ramachandran S, et al. Spinster 2, a sphingosine-1-phosphate transporter, plays a critical role in inflammatory and autoimmune diseases. FASEB J. 2015;29(12):5018\u201328.","journal-title":"FASEB J."},{"key":"1528_CR127","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3389\/fimmu.2020.01102","volume":"11","author":"F Naz","year":"2020","unstructured":"Naz F, Arish M. Battling COVID-19 pandemic: sphingosine-1-phosphate analogs as an adjunctive therapy? Front Immunol. 2020;11:1102.","journal-title":"Front Immunol."},{"key":"1528_CR128","doi-asserted-by":"crossref","first-page":"102180","DOI":"10.1016\/j.msard.2020.102180","volume":"42","author":"C Foerch","year":"2020","unstructured":"Foerch C, Friedauer L, Bauer B, Wolf T, Adam EH. Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Mult Scler Relat Disord. 2020;42:102180.","journal-title":"Mult Scler Relat Disord."},{"issue":"1","key":"1528_CR129","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41392-020-0191-1","volume":"5","author":"M Catanzaro","year":"2020","unstructured":"Catanzaro M, Fagiani F, Racchi M, Corsini E, Govoni S, Lanni C. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct Target Ther. 2020;5(1):84.","journal-title":"Signal Transduct Target Ther."},{"issue":"16","key":"1528_CR130","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s40265-017-0814-1","volume":"77","author":"G Comi","year":"2017","unstructured":"Comi G, Hartung HP, Bakshi R, Williams IM, Wiendl H. Benefit-risk profile of sphingosine-1-phosphate receptor modulators in relapsing and secondary progressive multiple sclerosis. Drugs. 2017;77(16):1755\u201368.","journal-title":"Drugs"},{"issue":"11","key":"1528_CR131","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd3248","volume":"9","author":"V Brinkmann","year":"2010","unstructured":"Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010;9(11):883\u201397.","journal-title":"Nat Rev Drug Discov."},{"issue":"6","key":"1528_CR132","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bcp.12129","volume":"76","author":"P Brossard","year":"2013","unstructured":"Brossard P, Derendorf H, Xu J, Maatouk H, Halabi A, Dingemanse J. Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol. 2013;76(6):888\u201396.","journal-title":"Br J Clin Pharmacol."},{"issue":"1","key":"1528_CR133","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/11596550-000000000-00000","volume":"51","author":"OJ David","year":"2012","unstructured":"David OJ, Kovarik JM, Schmouder RL. Clinical pharmacokinetics of fingolimod. Clin Pharmacokinet. 2012;51(1):15\u201328.","journal-title":"Clin Pharmacokinet."},{"issue":"5","key":"1528_CR134","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1080\/00498254.2017.1329568","volume":"48","author":"RP Dash","year":"2018","unstructured":"Dash RP, Rais R, Srinivas NR. Ponesimod, a selective sphingosine 1-phosphate (S1P1) receptor modulator for autoimmune diseases: review of clinical pharmacokinetics and drug disposition. Xenobiotica. 2018;48(5):442\u201351.","journal-title":"Xenobiotica"},{"issue":"8","key":"1528_CR135","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1080\/00498254.2020.1736688","volume":"50","author":"ML Boof","year":"2020","unstructured":"Boof ML, van Lier JJ, English S, Fischer H, Ufer M, Dingemanse J. Absorption, distribution, metabolism, and excretion of cenerimod, a selective S1P1 receptor modulator in healthy subjects. Xenobiotica. 2020;50(8):947\u201356.","journal-title":"Xenobiotica"},{"issue":"12","key":"1528_CR136","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.3390\/ijms18122636","volume":"18","author":"PE Juif","year":"2017","unstructured":"Juif PE, Baldoni D, Reyes M, et al. Pharmacokinetics, pharmacodynamics, tolerability, and food effect of cenerimod, a selective S1P1 receptor modulator in healthy subjects. Int J Mol Sci. 2017;18(12):2636.","journal-title":"Int J Mol Sci."},{"issue":"12","key":"1528_CR137","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00228-018-2533-2","volume":"74","author":"A Gardin","year":"2018","unstructured":"Gardin A, Gray C, Neelakantham S, et al. Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9\/3A4 inducer, in healthy subjects. Eur J Clin Pharmacol. 2018;74(12):1593\u2013604.","journal-title":"Eur J Clin Pharmacol."},{"key":"1528_CR138","unstructured":"Schreiber S, Morgan M, Christopher R, et al. Etrasimod (APD334), a Potent, Selective, Oral S1P Receptor Modulator With Preclinical Autoimmune Disease-modifying Activity Exhibits Favorable PK\/PD Properties in Healthy Volunteers (Abstract). http:\/\/www.arenapharm.com\/wp-content\/uploads\/2016\/12\/A23434E8.pdf. Accessed 7 Feb 2021."},{"key":"1528_CR139","doi-asserted-by":"crossref","first-page":"204062231989929","DOI":"10.1177\/2040622319899297","volume":"11","author":"K Hazel","year":"2020","unstructured":"Hazel K, O\u2019Connor A. Emerging treatments for inflammatory bowel disease. Ther Adv Chronic Dis. 2020;11:2040622319899297.","journal-title":"Ther Adv Chronic Dis."},{"issue":"10","key":"1528_CR140","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","volume":"18","author":"S Singh","year":"2020","unstructured":"Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis. Clin Gastroenterol Hepatol. 2020;18(10):2179-2191.e6.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"1528_CR141","unstructured":"PONVORYTM (ponesimod): US prescribing information 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/213498s000lbl.pdf. Accessed 5 May 2021."},{"key":"1528_CR142","unstructured":"ZEPOSIA\u00ae (ozanimod): US prescribing information 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209899s000lbl.pdf. Accessed 5 May 2021."}],"updated-by":[{"DOI":"10.1007\/s40265-021-01577-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:00:00Z","timestamp":1627603200000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01528-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01528-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01528-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T07:40:03Z","timestamp":1627630803000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01528-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,13]]},"references-count":142,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1528"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01528-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,13]]},"assertion":[{"value":"23 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2021","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-021-01577-z","URL":"https:\/\/doi.org\/10.1007\/s40265-021-01577-z","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by grants from the National Institutes of Health (DK108670, DK118927, AI149636), VA Merit BLRD-I01 BX003436 to JRN and San Diego Digestive Diseases Research Center (P30 DK120515).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material (data transparency)"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"TP-J, MA-L, and JR-N provided the concept and design, and drafted and revised the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}